This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Usmani, B. A. Articles by Nanus, D. M. Search for Related Content PubMed PubMed Citation Articles by Usmani, B. A. Articles by Nanus, D. M.

Methylation of the Neutral Endopeptidase Gene Promoter in Human Prostate Cancers¹

Laboratory of Urologic Oncology, Department of Urology [B. A. U., R. S., M. J., D. M. N.] and Division of Hematology and Medical Oncology, Department of Medicine [D. M. N.], Joan and Stanford I. Weill Medical College of Cornell University, New York, New York 10021; Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [C. N. P.]; and the James Buchanan Brady Urological Institute Research Laboratories, Johns Hopkins Hospital, Baltimore, Maryland 21287 [W-H. L., W. G. N., J. B. N.]

Neutral endopeptidase 24.11 (NEP) is a cell surface peptidase expressed by prostatic epithelial cells that cleaves and inactivates neuropeptide growth factors implicated in the growth of androgen-independent prostate cancer (PC). Decreased NEP expression in hormone-refractory metastatic PCs can result from hormonal therapies because NEP transcription is induced by androgens and down-regulated by androgen withdrawal. NEP is encoded by a gene that contains a 5' CpG island spanning a transcriptional regulatory region. In this study, we investigate whether DNA hypermethylation of the NEP promoter accompanies decreased NEP expression in PC cell lines and whether it occurs in human PC tissues in vivo. DNA isolated from PC cell lines and from normal and neoplastic human prostate tissues was restriction-digested with a methylation-sensitive restriction endonuclease and analyzed by Southern blot using a 5' sequence-specific NEP probe. Methylation-specific PCR was performed using PCR primers designed to discriminate between methylated and unmethylated alleles, and reverse transcription-PCR using NEP-specific primers was performed on cDNA extracted from PC cells treated with 5-aza-2'-deoxycytidine. Methylation of the NEP promoter was present in androgen-independent PC cell lines but not in androgen-dependent or small-cell derived PC cell lines and in 3 of 21 (14%) primary PCs from patients with androgen-dependent disease. Exposure of PC cells to the demethylating agent 5-aza-2'-deoxycytidine led to an increase in NEP transcripts in DU-145 and PC-3 cells. These data show that hypermethylation of the 5' CpG NEP island is associated with a loss of NEP expression in PC. Loss of NEP expression via hypermethylation of the NEP promoter may contribute to the development of neuropeptide-stimulated PCs.

This article has been cited by other articles:

				A. Fleischmann, T. Schlomm, H. Huland, J. Kollermann, P. Simon, M. Mirlacher, G. Salomon, F. H.K. Chun, T. Steuber, R. Simon, et al. Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients Clin. Cancer Res., December 1, 2008; 14(23): 7838 - 7842. [Abstract] [Full Text] [PDF]

				A. S Perry, R. Foley, K. Woodson, and M. Lawler The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377. [Abstract] [Full Text] [PDF]

				J. Gilbert, S. D. Gore, J. G. Herman, and M. A. Carducci The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation Clin. Cancer Res., July 15, 2004; 10(14): 4589 - 4596. [Abstract] [Full Text] [PDF]

				I. Osman, H. Yee, S. S. Taneja, B. Levinson, A. Zeleniuch-Jacquotte, C. Chang, C. Nobert, and D. M. Nanus Neutral Endopeptidase Protein Expression and Prognosis in Localized Prostate Cancer Clin. Cancer Res., June 15, 2004; 10(12): 4096 - 4100. [Abstract] [Full Text] [PDF]

				M. Sumitomo, T. Asano, J. Asakuma, T. Asano, D. M. Nanus, and M. Hayakawa Chemosensitization of Androgen-Independent Prostate Cancer with Neutral Endopeptidase Clin. Cancer Res., January 1, 2004; 10(1): 260 - 266. [Abstract] [Full Text] [PDF]

				F. Jiang and Z. Wang Identification of Androgen-Responsive Genes in the Rat Ventral Prostate by Complementary Deoxyribonucleic Acid Subtraction and Microarray Endocrinology, April 1, 2003; 144(4): 1257 - 1265. [Abstract] [Full Text] [PDF]

				M. A. Carducci, R. J. Padley, J. Breul, N. J. Vogelzang, B. A. Zonnenberg, D. D. Daliani, C. C. Schulman, A. A. Nabulsi, R. A. Humerickhouse, M. A. Weinberg, et al. Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial J. Clin. Oncol., February 15, 2003; 21(4): 679 - 689. [Abstract] [Full Text] [PDF]

				I. Dozmorov, M. R. Saban, N. P. Gerard, B. Lu, N.-B. Nguyen, M. Centola, and R. Saban Neurokinin 1 receptors and neprilysin modulation of mouse bladder gene regulation Physiol Genomics, February 6, 2003; 12(3): 239 - 250. [Abstract] [Full Text] [PDF]

				G. Garcia-Manero, J. Daniel, T. L. Smith, S. M. Kornblau, M.-S. Lee, H. M. Kantarjian, and J.-P. J. Issa DNA Methylation of Multiple Promoter-associated CpG Islands in Adult Acute Lymphocytic Leukemia Clin. Cancer Res., July 1, 2002; 8(7): 2217 - 2224. [Abstract] [Full Text] [PDF]

				M. Sumitomo, M. I. Milowsky, R. Shen, D. Navarro, J. Dai, T. Asano, M. Hayakawa, and D. M. Nanus Neutral Endopeptidase Inhibits Neuropeptide-mediated Transactivation of the Insulin-like Growth Factor Receptor-Akt Cell Survival Pathway Cancer Res., April 1, 2001; 61(8): 3294 - 3298. [Abstract] [Full Text]